NurExone Biologic Inc. develops exosome-based therapies targeting central nervous system injuries. While the company has a solid liquidity position with a current ratio of 1.94 and low debt levels (0.06), it faces significant profitability challenges, reflected in its negative ROE (-120.5%) and ROA (-64.5%). The recent price drop of 3.64% raises concerns about market sentiment. Overall, while the innovative approach is promising, financial health indicators suggest a need for improvement in operational efficiency and profitability.
Loading financial metrics...
Company is burning $513K per quarter with $1.2M in cash. Approximately 2.4 quarters of runway at current burn rate.
Company posted a loss of $-3.5M over the last year, representing Infinity% of revenue.
Fortress balance sheet: cash covers total debt 13×, providing significant financial flexibility.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)